VRCA
Verrica Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.38
−1.17%Oct 22, 2026, 12:00 UTC
Verrica Pharmaceuticals achieved the revenue, growth and operational milestones that increased the maximum commitment under its credit facility by $15.0 million, making the full $27.5 million available.
Source:Sep 10, 2026, 12:05 UTC
Verrica Pharmaceuticals announced it will present data on YCANTH and VP-315 at two upcoming dermatology conferences.
Source:Aug 27, 2026, 12:00 UTC
Verrica Pharmaceuticals completed enrollment in the first pivotal Phase 3 trial (COVE-2) evaluating YCANTH for the treatment of common warts, with topline data expected in Q1 2027.
Source:Aug 7, 2026, 19:05 UTC
Verrica Pharmaceuticals announced a credit facility that management said could extend its cash runway into 2028.
Source:Aug 7, 2026, 11:24 UTC
Verrica Pharmaceuticals Inc. held its Q2 2026 earnings call on August 7, 2026.
Jul 21, 2026, 12:00 UTC
Verrica Pharmaceuticals entered into an exclusive distribution, marketing and supply agreement with Medomie Pharma to commercialize YCANTH for molluscum contagiosum in Israel.
Source:Jun 9, 2026, 00:00 UTC
Verrica Pharmaceuticals Inc. elected Paul B. Manning and Lawrence Eichenfield as directors effective June 5, 2026.